Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial
Titel:
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial
Auteur:
Abboud, Miguel R Cançado, Rodolfo D De Montalembert, Mariane Smith, Wally R Rimawi, Hala Voskaridou, Ersi Güvenç, Birol Ataga, Kenneth I Keefe, Deborah Grosch, Kai Watson, Jimmy Reshetnyak, Evgeniya Nassin, Michele L Dei-Adomakoh, Yvonne